SynonymsQuercetin, Xanthaurine, Quercitol, and Quertine
The GLP-1RAs, particularly semaglutide, are now used on a global scale for diabetes and obesity, and emerging pharmacovigilance reports suggest that some patients may experience oral and salivary symptoms during therapy, including xerostomia, dysgeusia, oral hypoesthesia, and throat discomfort [1]
A clinician may: Review your most recent Ozempic dose Assess gastrointestinal tolerance Evaluate weight-loss progress Discuss expectations and lifestyle support For example, a patient using Ozempic for several months explored enhanced support
The average age of onset is between 50 and 70 years of age (59)
However, tirzepatide 5 mg produced greater weight loss (-7.8 kg vs -5.7 kg), so it is not a true equivalency